Drug Trial Radar · NCT04659707
Hyperpolarized 129Xe MRI of Survivors of COVID-19
Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Feb 22, 2021
Primary completion
Jan 1, 2025
Study completion May 1, 2025
Sponsor
- Lead sponsor
- University of Kansas Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate pulmonary function of patients recovering from mild, moderate, and severe COVID-19 disease using hyperpolarized 129Xe MRI.
Conditions
- Covid19
Interventions
Hyperpolarized Xe129Drug
Subjects will inhale up to 4 doses of hyperpolarized Xenon gas in order to image pulmonary function.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ventilation Defect PercentageTime frame: Baseline
- Ventilation Defect PercentageTime frame: 6-months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Kansas Medical Center
Kansas City, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.